The Current Ratio as of November 2024 (TTM) for ADMA Biologics, Inc. (ADMA) is 6.87

According to ADMA Biologics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 6.87. This represents a change of 15.62% compared to the average of 5.95 of the last 4 quarters.

ADMA Biologics, Inc. (ADMA) Historical Current Ratio (quarterly & annually)

How has ADMA Current Ratio performed in the past?

The mean historical Current Ratio of ADMA Biologics, Inc. over the last ten years is 5.68. The current 6.87 Current Ratio has changed 12.01% with respect to the historical average. Over the past ten years (40 quarters), ADMA's Current Ratio was at its highest in in the March 2020 quarter at 11.90. The Current Ratio was at its lowest in in the March 2017 quarter at 1.21.

ADMA Biologics, Inc. (ADMA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of ADMA Biologics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

ADMA Biologics, Inc. (ADMA) Average Current Ratio

How has ADMA Current Ratio performed in the past?

The current Current Ratio of ADMA Biologics, Inc. (ADMA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

ADMA Biologics, Inc. (ADMA) Current Ratio vs. Peers

How is ADMA’s Current Ratio compared to its peers?

ADMA Biologics, Inc.’s Current Ratio is greater than Atara Biotherapeutics, Inc. (0.42), less than Fate Therapeutics, Inc. (9.18), greater than Sana Biotechnology, Inc. (5.20), less than Caribou Biosciences, Inc. (8.75), greater than Arcus Biosciences, Inc. (5.14), greater than TFF Pharmaceuticals, Inc. (1.63), greater than INmune Bio, Inc. (2.59), less than Anebulo Pharmaceuticals, Inc. (13.46), greater than Abcam plc (1.35), less than AN2 Therapeutics, Inc. (10.61), less than 89bio, Inc. (13.92), greater than Madrigal Pharmaceuticals, Inc. (5.98), less than Pliant Therapeutics, Inc. (14.47), greater than Arcellx, Inc. (6.01), greater than Stoke Therapeutics, Inc. (6.67), greater than Protalix BioTherapeutics, Inc. (1.33), greater than Cidara Therapeutics, Inc. (4.25), greater than Akebia Therapeutics, Inc. (1.04), greater than X4 Pharmaceuticals, Inc. (6.07), greater than Seres Therapeutics, Inc. (1.38), greater than Vaxart, Inc. (4.54), greater than iBio, Inc. (4.08), greater than Tonix Pharmaceuticals Holding Corp. (1.15), greater than BioCryst Pharmaceuticals, Inc. (2.82),

Build a custom stock screener for ADMA Biologics, Inc. (ADMA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ADMA Biologics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ADMA Biologics, Inc. (ADMA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ADMA Biologics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.